Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials.
Controls
Dopamine transporter
Healthy controls
SPECT
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
03
2021
revised:
20
08
2021
accepted:
22
08
2021
pubmed:
6
9
2021
medline:
20
1
2022
entrez:
5
9
2021
Statut:
ppublish
Résumé
To evaluate possible differences between brain dopamine transporter (DAT) binding in a group of symptomatic parkinsonism patients without dopaminergic degeneration and healthy individuals. Dopaminergic neuroimaging studies of Parkinson's disease (PD) have often used control groups formed from symptomatic patients with apparently normal striatal dopamine function. We sought to investigate whether symptomatic patients can be used to represent dopaminergically normal healthy controls. Forty healthy elderly individuals were scanned with DAT [ DAT binding in symptomatic patients was 8.6% higher in the posterior putamen than in healthy controls (p = 0.03). Binding correlated negatively with age in both groups but not with motor symptom severity, cognitive function or depression ratings. Putaminal DAT binding, as measured with [
Sections du résumé
OBJECTIVE
To evaluate possible differences between brain dopamine transporter (DAT) binding in a group of symptomatic parkinsonism patients without dopaminergic degeneration and healthy individuals.
BACKGROUND
Dopaminergic neuroimaging studies of Parkinson's disease (PD) have often used control groups formed from symptomatic patients with apparently normal striatal dopamine function. We sought to investigate whether symptomatic patients can be used to represent dopaminergically normal healthy controls.
METHODS
Forty healthy elderly individuals were scanned with DAT [
RESULTS
DAT binding in symptomatic patients was 8.6% higher in the posterior putamen than in healthy controls (p = 0.03). Binding correlated negatively with age in both groups but not with motor symptom severity, cognitive function or depression ratings.
CONCLUSIONS
Putaminal DAT binding, as measured with [
Identifiants
pubmed: 34482280
pii: S2213-1582(21)00251-5
doi: 10.1016/j.nicl.2021.102807
pmc: PMC8416950
pii:
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102807Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.